Jianxin Ni
Urologist at Xi'an People's Hospital and senior author of a 2026 multicentre study of everolimus for TSC kidney tumours, with further work on prostate cancer
Department of Urology, Urology and Nephrology Hospital, Xi'an People's Hospital (Xi'an Fourth Hospital), Northwest University
Jianxin Ni is the last author, usually the person who leads the project, of a 2026 prospective study from several Chinese centres on everolimus for kidney angiomyolipomas in tuberous sclerosis complex (GAO2026B). In TSC the brake on mTORC1, the cell's growth-control complex, is missing, and everolimus puts part of that brake back. In 183 patients the drug shrank tumours by half or more in 44% at 3 months and 83% at 6 months. Tumours with little fat responded better than fat-rich ones, so a scan of tumour fat could help predict who benefits. A lower dose looked similar and caused fewer mouth ulcers, but only in an exploratory, non-randomised comparison. Tumours regrew after the drug was stopped.
PubMed lists about ten papers with Ni at the urology department of Xi'an People's Hospital since 2023. They include a 2026 study in cells and mice showing that the protein PEAK1 helps prostate cancer resist the chemotherapy drug docetaxel by pushing nearby immune cells, macrophages, into a tumour-helping state, and a 2025 rat study on salt, IL-17 and cholesterol. No personal institutional page was found, so the position shown is the one on these papers.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2026 | H | Tumor fat composition predicts response to everolimus and supports low-dose therapy in TSC-associated renal angiomyolipomas: a multicenter prospective study GAO2026B Last author who led the multicentre cohort linking tumour fat content to everolimus response in TSC angiomyolipoma. |
Co-authors in the Atlas 1
People with a profile here who share at least one study with Jianxin Ni.
ShowHide
- Ke Gao Urology researcher at Xi'an People's Hospital and first author of a 2026 multicentre study showing that the fat content of TSC kidney tumours predicts how well they shrink on everolimus
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.